8-K: CompoSecure Addresses Shareholder Lawsuits, Supplements Proxy for Husky Merger

CompoSecure, Inc. has issued supplemental disclosures to its proxy statement to address shareholder demand letters and lawsuits challenging the proposed $3.953 billion cash and stock merger with Husky Technologies Limited.

Summary

• CompoSecure, Inc. is combining with Husky Technologies Limited for aggregate consideration of approximately $3.953 billion in cash and 55,297,297 shares of CompoSecure Class A Common Stock.
• Concurrently, CompoSecure entered into purchase agreements to issue and sell 106,056,083 shares of Common Stock in a private placement at a purchase price of $18.50 per share, for an aggregate of approximately $1.96 billion.
• A special meeting of CompoSecure shareholders is scheduled for December 23, 2025, at 10:00 a.m. Eastern Time, to approve the issuance of Common Stock for the transactions.
• Several purported shareholders have sent demand letters and filed three lawsuits alleging material omissions or disclosure deficiencies in the Proxy Statement, seeking corrective disclosures or injunctions against the transactions.
• CompoSecure believes these claims are without merit but is voluntarily providing supplemental disclosures to reduce litigation risk and minimize costs and uncertainties inherent in litigation, without admitting any liability or wrongdoing.
• The supplemental disclosures update sections of the financial advisor's analysis, including Comparable Company Analysis, Selected Precedent Transaction Analysis, Discounted Cash Flow Analysis for both Husky and CompoSecure, and Pro Forma Combined Company Analysis.
• Morgan Stanley, CompoSecure's financial advisor, has received between $10 million and $20 million in fees from Platinum Equity (a seller) for financing services in the two years prior to the disclosure date and has other ongoing assignments with Platinum Equity.

Sentiment

Score: 4

Explanation: The filing addresses significant shareholder litigation and potential conflicts of interest with the financial advisor, which are negative. However, the company is taking steps to mitigate these risks by providing supplemental disclosures, which is a positive action. The underlying merger transaction itself is large and potentially transformative, but the immediate context is defensive.

Positives

• CompoSecure is proactively providing supplemental disclosures to mitigate litigation risks and avoid potential transaction delays, without admitting any wrongdoing.
• The company maintains its belief that the claims asserted in the demand letters and complaints regarding the Proxy Statement are without merit and that no supplemental disclosure was legally required.

Negatives

• Three separate lawsuits have been filed by purported shareholders alleging that the Proxy Statement is materially incomplete and misleading, misrepresents/omits material information, and/or involved conflicted individuals.
• Shareholder demand letters also allege disclosure deficiencies that prejudice shareholders' ability to make a fully informed decision concerning the Transactions.
• The lawsuits seek, among other things, injunctions barring consummation of the Transactions or, if consummated, rescinding it or awarding damages.
• A purported shareholder has sent a demand pursuant to Section 220 of the Delaware General Corporation Law seeking to inspect certain company books and records related to the Transactions.
• Morgan Stanley, the financial advisor, has significant prior and ongoing financial relationships with Platinum Equity (a seller), with fees from Platinum Equity potentially exceeding those from CompoSecure for the current transaction, raising potential conflict of interest concerns.

Risks

• The risk that the Transactions may not be completed in a timely manner or at all.
• Failure to obtain required approvals, including regulatory approvals and the Company Stockholder Approval.
• The occurrence of any event that could give rise to termination of the Share Purchase Agreement.
• The effect of the announcement, pendency, or consummation of the Transactions on the parties' business relationships, operations, financial, and accounting matters.
• Risks that the expected benefits of the Transactions, including financial projections, estimates, and outlook, may not be fully realized or may take longer to realize than expected.
• Risks related to financing the Transactions.
• Costs related to the Transactions.
• Potential litigation and/or regulatory actions relating to the Transactions, including the demand letters and Complaints described.
• General economic, market, industry, and competitive conditions.

Future Outlook

The filing primarily focuses on addressing past disclosures and current legal challenges related to the Husky acquisition. Forward-looking statements are general disclaimers about the risks of the transaction not completing or expected benefits not being realized, and the company undertakes no obligation to update them except as required by law.

Management Comments

• "CompoSecure believes that the claims asserted in the demand letters and in the Complaints regarding the Proxy Statement are without any merit and that no supplemental disclosure is required under applicable laws."
• "However, in order to reduce the risk of the Complaints or demand letters delaying or adversely affecting the Transactions and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing whatsoever, CompoSecure has determined to voluntarily supplement the Proxy Statement..."
• "To the contrary, the Company specifically denies all allegations that further disclosure of any kind was or is required to supplement the Proxy Statement under applicable laws."

Industry Context

The filing provides updated comparable company multiples for 'Industrial After Market and Consumable Peers' and 'Food and Beverage-Oriented Machinery Peers,' as well as selected precedent transaction analyses, indicating the broader M&A and valuation landscape for industrial and machinery companies. The transaction itself represents a significant M&A event within the specialized manufacturing sector.

Comparison to Industry Standards

• Comparable Company Multiples for Industrial After Market and Consumable Peers (2025E AV/EBITDA) include Nordson Corporation (16.9x), Lincoln Electric Holdings, Inc. (16.6x), ESAB Corporation (15.3x), and Donaldson Company, Inc. (14.7x).
• Comparable Company Multiples for Food and Beverage-Oriented Machinery Peers (2025E AV/EBITDA) include JBT Marel Corporation (14.4x), GEA Group AG (11.1x), Hillenbrand Inc. (8.5x), Sealed Air Corporation (8.1x), and Krones AG (6.0x).
• Selected Precedent Transaction AV/LTM EBITDA multiples since 2017 range from 8.8x (Milacron, February 2025) to ~19x (IMA Group, July 2023). The Husky Injection Molding Systems International Ltd. acquisition by Platinum Equity in December 2017 had an AV/LTM EBITDA of 11.6x.
• The implied value of the current Husky transaction consideration of $4.976 billion falls within Morgan Stanley's discounted cash flow implied enterprise value range for Husky of approximately $4.917 billion to $6.961 billion.

Corporate Governance

Legal Proceedings

• Several purported shareholders sent demand letters generally alleging that the Proxy Statement omitted material information or otherwise had disclosure deficiencies that prejudice the ability of the Company shareholders to make a fully informed decision concerning the Transactions.
• Three separate complaints were filed by purported shareholders: Michael Kent v. CompoSecure, Inc. et. al. (Case No. 656261/2025) and Richard Lawrence v. CompoSecure, Inc. et. al. (Case No. 656243/2025) in the Supreme Court of the State of New York, County of New York, for negligence and negligent misrepresentation and concealment.
• A third complaint, Steven Lacoff v. David Cote et. al. (Case No. SOM-C-012082-25), was filed in the Superior Court of New Jersey against the Company and its directors, for misrepresentation and concealment in violation of New Jersey statutory and/or common law.
• The Complaints allege that the Proxy Statement is materially incomplete and misleading, misrepresents and/or omits material information necessary for shareholders to make an informed decision, and/or involved conflicted individuals.
• The Complaints seek, among other things, injunctions barring consummation of the Transactions or, in the event that the Transactions are consummated, rescinding it or awarding damages.
• A purported Company shareholder sent a demand pursuant to Section 220 of the Delaware General Corporation Law seeking to inspect certain Company books and records in connection with, among other things, the Transactions.

Related Party Transactions

• Morgan Stanley, CompoSecure's financial advisor, or an affiliate thereof, is a lender to Platinum Equity (a seller in the Husky transaction) and/or certain of its affiliates with respect to revolving credit facilities.
• In the two years prior to the disclosure date, Morgan Stanley and its affiliates received aggregate fees of between $10 million and $20 million for financing services provided to Platinum and/or certain of its affiliates.
• Morgan Stanley is also mandated on certain financial advisory and financing assignments for Platinum and/or certain of its affiliates unrelated to the Transactions, for which customary fees are expected, and such fees could be greater, in the aggregate, than the fees Morgan Stanley would receive from CompoSecure in the Transactions.
• Morgan Stanley, its affiliates, directors or officers, including individuals working with CompoSecure in connection with the Transactions, may have committed and may commit in the future to invest in private equity funds managed by Platinum.

Stakeholder Impact

• Shareholders are directly impacted by the proposed merger and private placement, requiring their approval, and the lawsuits and supplemental disclosures aim to ensure they have sufficient information for an informed decision.
• CompoSecure faces legal challenges and costs associated with litigation, potentially delaying or jeopardizing the Husky acquisition, requiring management to expend resources to address these issues.
• Husky Technologies Limited, as the target company, has its future tied to the successful completion of the transaction.
• Platinum Equity Advisors, LLC, as a seller in the transaction, has interests aligned with the successful and timely completion of the merger.
• Investors participating in the private placement will become significant shareholders in CompoSecure.

Next Steps

• A special meeting of CompoSecure shareholders will be held virtually on December 23, 2025, at 10:00 a.m. Eastern Time, to approve the issuance of Common Stock for the transactions.
• Shareholders are urged to read the Proxy Statement (including any amendments or supplements thereto) and any other relevant documents filed or to be filed with the SEC carefully and in their entirety.

Key Dates

Recommendation

The filing highlights significant legal challenges and potential conflicts of interest surrounding a major acquisition. While management asserts the claims are without merit and is taking steps to provide additional disclosures, the existence of multiple lawsuits and a Section 220 demand creates uncertainty. The potential for delays or even termination of the transaction, coupled with the financial advisor's substantial prior relationship with a seller, warrants caution. Investors should hold to monitor the outcome of the shareholder vote and legal proceedings, as these factors will significantly influence the company's future trajectory and valuation. A 'buy' would be premature given the legal overhang, and a 'sell' might be an overreaction if the transaction ultimately proceeds as planned.

Keywords

CompoSecure, Husky Technologies, Merger, Acquisition, Share Purchase Agreement, Private Placement, Proxy Statement, Shareholder Lawsuit, Litigation, SEC Filing, 8-K, Corporate Governance, Financial Advisor, Morgan Stanley, Platinum Equity, Stock Issuance, CMPO, NYSE